TSHA
NASDAQ · Biotechnology
Taysha Gene Therapies Inc
$4.43
+0.30 (+7.26%)
Financial Highlights (FY 2026)
Revenue
9.27M
Net Income
-99,337,915
Gross Margin
—
Profit Margin
-1,071.6%
Rev Growth
—
D/E Ratio
0.63
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 50.0% | 50.0% | 50.0% |
| Operating Margin | -1,097.5% | 19.1% | 20.3% | 19.2% |
| Profit Margin | -1,071.6% | 17.5% | 16.9% | 15.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.27M | 249.41M | 242.81M | 217.48M |
| Gross Profit | — | 124.71M | 121.41M | 108.74M |
| Operating Income | -101,698,686 | 47.60M | 49.27M | 41.66M |
| Net Income | -99,337,915 | 43.60M | 41.01M | 33.31M |
| Gross Margin | — | 50.0% | 50.0% | 50.0% |
| Operating Margin | -1,097.5% | 19.1% | 20.3% | 19.2% |
| Profit Margin | -1,071.6% | 17.5% | 16.9% | 15.3% |
| Rev Growth | — | +22.8% | -6.9% | +4.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 236.54M | 344.80M | 297.64M | 350.89M |
| Total Equity | 378.41M | 452.11M | 514.03M | 439.34M |
| D/E Ratio | 0.63 | 0.76 | 0.58 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -105,570,882 | 65.17M | 60.77M | 54.08M |
| Free Cash Flow | — | 41.80M | 46.40M | 32.89M |